Tomblyn Marcie R, Tallman Martin S
Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
Semin Oncol. 2003 Aug;30(4):502-8. doi: 10.1016/s0093-7754(03)00234-3.
In the past three decades, improvements in the treatment of acute myeloid leukemia (AML) have increased survival in patients younger than 55 years without significant survival impact in older individuals. Unfortunately, many patients, regardless of age at diagnosis, will eventually die from their disease. Advances in the development of targeted therapies have proven beneficial in chronic myeloid leukemia and lymphoma. Gemtuzumab ozogamicin (GO; Mylotarg, Wyeth-Ayerst, St Davids, PA), a monoclonal antibody conjugated to calicheamicin, targets the CD33 antigen found on the surface of more than 80% of AML leukemic blasts. GO is approved for relapsed disease in patients older than 60 years, but is being evaluated in combination with chemotherapy, in the setting of hematopoietic stem cell transplant, and in high-risk myelodysplasia.
在过去三十年中，急性髓系白血病（AML）治疗方法的改进提高了55岁以下患者的生存率，但对老年患者的生存影响不大。不幸的是，许多患者无论诊断时的年龄如何，最终都会死于该疾病。靶向治疗的发展已被证明对慢性髓系白血病和淋巴瘤有益。吉妥珠单抗奥唑米星（GO；Mylotarg，惠氏-艾尔斯特，宾夕法尼亚州圣大卫斯）是一种与卡奇霉素偶联的单克隆抗体，靶向80%以上AML白血病母细胞表面发现的CD33抗原。GO被批准用于60岁以上复发疾病的患者，但正在与化疗联合、在造血干细胞移植背景下以及高危骨髓增生异常中进行评估。
